Anti-B cell CAR-T therapy in multiple sclerosis is simply a more profound immunoablation? Yes

Haghikia A Hegelmaier T Wolleschak D , et al. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol 2023; 22(12): 1104–1105.

Fischbach F Richter J Pfeffer LK , et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med 2024; 5(6): 550–558.

Lassmann H . Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol 2018; 9: 3116.

Kansal R Richardson N Neeli I , et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med 2019; 11(482): eaav1648.

Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis [Internet]. Roche Investor Updates, 2025. https://www.roche.com/investors/updates/inv-update-2025-04-02b

Darlington PJ Touil T Doucet JS , et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol 2013; 73(3): 341–354.

Lu JQ Storek J Metz L , et al. Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. Arch Neurol 2009; 66(1): 116–120.

Floersh H . Kyverna’s CAR-T Relapse in Lupus Dents Autoimmune Hopes Amid Biotech Gold Rush [Internet]. Washington, DC: Fierce Biotech, 2024. https://www.fiercebiotech.com/biotech/kyverna-reports-relapse-early-stage-car-t-lupus-trial (accessed 21 May 2025).

Schwab N Wiendl H . Learning CNS immunopathology from therapeutic interventions. Sci Transl Med 2023; 15(721): eadg7863.